B., S., C., P., A., B., D., T., L., P., M., L., . . . K., E. (2023). Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial.
Citación estilo ChicagoB., Strober, et al. Bimekizumab Efficacy and Safety in Patients With Moderate to Severe Plaque Psoriasis: Two-year Interim Results From the Open-label Extension of the Randomized BE RADIANT Phase 3b Trial. 2023.
Cita MLAB., Strober, et al. Bimekizumab Efficacy and Safety in Patients With Moderate to Severe Plaque Psoriasis: Two-year Interim Results From the Open-label Extension of the Randomized BE RADIANT Phase 3b Trial. 2023.
Precaución: Estas citas no son 100% exactas.